The internal rate of return on ValueAct’s investment in pharmaceuticals giant Valeant is more than 40%. Jeff Ubben is among the investors who cashed in the most.
For the CEO ValueAct Capital, the Valeant investment has been huge. ValueAct has invested $650 million over the years and turned it into $4.3 billion, which includes $1.8 billion of realized profits. Ubben has spent time on Valeant’s board and his hedge fund now manages $19 billion.
Photo: (Ann Johansson/Corbis)